2026-04-13T16:55:02Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2216712025-12-05T12:02:03Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Sureda, Anna author Garcia Sanz, Ramón author Domingo Domènech, Eva author Capote, Francisco Javier author Gutiérrez García, Antonio Manuel author Rodriguez Izquierdo, Antonia author Aguiar Bujanda, David author Giraldo, Pilar author Infante, María Stefania author López Jiménez, Javier author Martínez, Carmen author Sánchez Gonzalez, Blanca author Ortiz Romero, Pablo Luís author Grande, Marta author Baeza Montañez, Lourdes author 2025-06-20T10:07:41Z 2025-06-20T10:07:41Z 2025-03-28 2025-06-10T12:59:48Z Background/Objectives: Brentuximab vedotin (BV) has been shown to be effective in the treatment of classical Hodgkin's lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and CD30-positive cutaneous T-cell lymphoma (CTCL). This study aimed to evaluate the effectiveness and safety of BV retreatment in patients with relapsed/refractory cHL, sALCL, and CD30-positive CTCL. Methods: This multicenter, non-interventional, retrospective medical chart review study analyzed medical records from 43 patients retreated with BV in Spain. Patients were included if they had relapsed or refractory cHL, sALCL, or CD30-positive CTCL and were previously treated with BV. Demographic characteristics, disease stage, response to treatment, survival outcomes, and adverse events were analyzed. Results: The study population included 16 patients with cHL, 13 with sALCL, and 14 with CTCL. The majority were male (58.1%) with a mean age of 46.2 years and baseline ECOG scores of 0-1. Among cHL and sALCL patients, disease stage, according to the Ann Arbor classification, ranged from I to IVB, while in CTCL, EORTC clinical stages ranged from IA to IVB. The overall response rate to BV retreatment was 76.7%, with the highest response observed in sALCL (92.3%). Complete remission was achieved in 60.5% of patients. Median progression-free survival was 25.4 months, and overall survival reached 50 months. Treatment failure occurred in 37.2% of patients. BV was generally well tolerated, with peripheral neuropathy being the most frequently reported adverse event. Conclusions: The BELIEVE study is the largest study to date demonstrating that retreatment with BV is an effective and well-tolerated option for patients with relapsed or refractory CD30-positive malignancies. Malaltia de Hodgkin Medicaments antineoplàstics Hodgkin's disease Antineoplastic agents Retreatment with Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain-The BELIEVE Study